NCT04305470 - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

November 7, 2022

Study Completion Date

December 13, 2022

Conditions

Meningioma

Interventions

DRUG

Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)

One time oral dose on day of surgery (20 mg/kg bodyweight)

Trial Locations (17)

1090

Medical University of Vienna, Vienna

11220

NYU Langone Health, Brooklyn

15213

UPMC, Pittsburgh

19104

University of Pennsylvania- Penn Medicine, Philadelphia

33136

University of Miami, Coral Gables

33176

Baptist Health South Florida, Miami

48202

Henry Ford Health System, Detroit

55905

Mayo Clinic Rochester, Rochester

62702

Southern Illinois University, Springfield

77030

MD Anderson, Houston

80113

Swedish Medical Center, Englewood

85054

Mayo Clinic, Phoenix

90033

Keck Hospital of USC, Los Angeles

92093

University of California San Diego, La Jolla

92868

Providence St. Joseph Hospital, Orange

02114

Massachusetts General Hospital, Boston

Unknown

University Hospital Münster, Münster